Su1345 Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4 Year Prospective Study

Hashash, Jana G.; Rivers, Claudia M. Ramos; Regueiro, Miguel; Barrie, Arthur; Schwartz, Marc D.; Baidoo, Leonard; Swoger, Jason M.; Dunn, Michael A.; Binion, David G.

doi:10.1016/s0016-5085(14)61589-4

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 In line with previous cohorts, 25 the source of most cases of bacteremia were not related directly to IBD complications, despite the fact that IBD exacerbation was the most common indication of hospitalisation accounting for 27% of admissions. As patients with IBD are exposed repeatedly to antibiotic therapies, 31 the prevalence of ARB within this group in our cohort was 13.7%. Half of the ARBs in our cohort were related to ESBL-producing E. coli and 70% were acquired during NB.…”

Section: Discussionmentioning

confidence: 79%

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9‐year cohort study

et al. 2020

View full text Add to dashboard Cite

Background Patients with inflammatory bowel disease might be at increased risk of invasive bacterial infections. Objectives The objective of this study was to identify the rate of bacteremia in hospitalised patients with inflammatory bowel disease and risk factors. Methods An observational cohort of hospitalised patients with inflammatory bowel disease, aged 16–80 years, from 2008 to 2017 in a large tertiary hospital. Patients with Charlson comorbidity index of 2 or greater were excluded. Patients with one or more positive blood culture were reviewed. Logistic regression was used to evaluate risk factors for bacteremia. Results Of 5522 admitted patients, only 1.3% had bacteremia (73/5522) (39, Crohn’s disease; 25, ulcerative colitis; nine, unclassified inflammatory bowel disease). The most common pathogen was Escherichia coli (19/73 patients). The mortality rate at 30 days of patients with bacteremia was 13.7% (10/73). Longer hospitalisations (mean length of stay (21.6 ± 31.0 vs. 6.4 ± 16.0 days; P < 0.0001) and older age (mean age 47.5 ± 18.0 vs. 40.2 ± 15.4 years, P < 0.0001)) were associated with an increased risk of bacteremia. In multivariate analysis, treatment with either anti-tumour necrosis factor α, purine analogues, steroids or amino salicylates was not associated with an increased risk of bacteremia. Risk was greatest among patients aged 65 years or older (relative risk 2.84, 95% confidence interval 1.6–4.8; P = 0.0001) relative to those under 65 years. Conclusion Age over 65 years, but not inflammatory bowel disease-related medications, is associated with an increased risk of bacteremia in hospitalised patients with inflammatory bowel disease.

show abstract

Section: Discussionmentioning

confidence: 79%

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9‐year cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CD is a disorder with multifactorial aetiology in which genetics and environment are deeply involved in determining the manifestation of the disease. In fact, risk factors include genetic determinants (so far, the most significant genetic associations have been found in NOD2, IL23R, and ATG16L1 genes) and acquired determinants, such as a diet low in carbohydrates, smoking, use of non-steroidal anti-inflammatory drug (NSAIDs) and an altered intestinal microbiome [3][4][5]. The manifestations of CD and UC are similar, although in UC the patient more commonly presents with diarrhoea and bleeding, whereas the patient with CD typically presents with watery diarrhoea and more nuanced symptoms [6].…”

Section: Introductionmentioning

confidence: 99%

The Role of Magnetic Resonance Enterography in Crohn’s Disease: A Review of Recent Literature

et al. 2022

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is the term used to identify a form of chronic inflammation of the gastrointestinal tract that primarily contemplates two major entities: ulcerative colitis (UC) and Crohn’s disease (CD). The classic signs are abdominal pain and diarrhoea that correlate with the localization of gastro-enteric disease, although in this pathology extraintestinal symptoms may coexist. The diagnosis of CD relies on a synergistic combination of clinical, laboratory (stool and biochemical), cross-sectional imaging evaluation, as well as endoscopic and histologic assessments. The purpose of this paper is to prove the role of imaging in the diagnosis and follow-up of patients with CD with particular focus on recent innovations of magnetic resonance enterography (MRE) as a pivotal diagnostic tool, analysing the MRE study protocol and imaging features during the various phases of disease activity and its complications.

show abstract

Su1345 Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease: A 4 Year Prospective Study

Cited by 2 publications

References 0 publications

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9‐year cohort study

Risk of bacteremia in hospitalised patients with inflammatory bowel disease: a 9‐year cohort study

The Role of Magnetic Resonance Enterography in Crohn’s Disease: A Review of Recent Literature

Contact Info

Product

Resources

About